Breaking the Barrier: The Future of Clinical Trials and Drug Development in the Biotech Industry”.

Recent advances in identifying and testing therapies, a more precise understanding of disease, and a sense of urgency to address public health issues may change the trend of high failure rates during clinical trials in drug development, according to life science leaders. During the Milken Institute 2024 Global Conference, a panel of biomedical experts highlighted recent scientific breakthroughs such as mRNA vaccines and the first CRISPR-based therapy to receive regulatory approval as examples of what is achievable.

Noubar Afeyan, founder and CEO of Flagship Pioneering, emphasized the need for the industry to streamline and reconsider drug development to maintain a momentum of success in the future. He noted that changing this mindset could lead to faster, more cost-effective innovation in drug development. To access daily coverage and analysis of the biotech sector, including exclusive content like this article, readers can subscribe to STAT+ for unlimited access to award-winning journalism and exclusive events.